by Jeffrey W. Eaton, Cheryl C. Johnson, Simon Gregson
Clin Infect Dis (2017) 65 (3): 522-525, Published: 24 April 2017
The authors compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons before antiretroviral therapy (ART) initiation to the costs of ART provision to misdiagnosed HIV-negative persons. Savings from averted unnecessary ART costs were greater than retesting costs within 1 year using assumptions representative of HIV testing performance in programmatic settings. Countries should implement re-testing before ART initiation.